PhoenixBio Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
69
- Stock Symbol
-
6190
- Investments
-
1
- Share Price
-
$1.56
- (As of Monday Closing)
PhoenixBio General Information
Description
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
Contact Information
Website
www.phoenixbio.comCorporate Office
- 3-4-1 Kagamiyama
- Higashihiroshima, Hiroshima 739-0046
- Japan
Corporate Office
- 3-4-1 Kagamiyama
- Higashihiroshima, Hiroshima 739-0046
- Japan
PhoenixBio Stock Performance
As of 16-Nov-2026, PhoenixBio’s stock price is $1.56. Its current market cap is $6.36M with 4.07M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.56 | $1.63 | $1.49 - $4.10 | $6.36M | 4.07M | 9.9K | $0.02 |
PhoenixBio Financials Summary
As of 30-Jun-2026, PhoenixBio has a trailing 12-month revenue of $9.2M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 4,209 | 6,735 | 4,876 | 6,993 |
| Revenue | 9,224 | 10,387 | 10,108 | 11,872 |
| EBITDA | 1,065 | (2,674) | 567 | |
| Net Income | 97 | 831 | (2,944) | 183 |
| Total Assets | 12,775 | 13,716 | 15,272 | 17,941 |
| Total Debt | 1,853 | 3,044 | 3,778 | 4,783 |
PhoenixBio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PhoenixBio Patents
PhoenixBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026141509-A1 | Mouse hepatocyte gene regulated-type human liver model animal | Pending | 26-Dec-2024 | ||
| WO-2026029135-A1 | Amyloid β accumulation model animal | Pending | 01-Aug-2024 | ||
| WO-2024204718-A1 | Screening method for high specific gravity lipoprotein particle function promoter | Inactive | 31-Mar-2023 | ||
| EP-4673530-A1 | Role of hepatocyte-derived extracellular matrix and coagulation factors for the fate restoration and maintenance of human hepatocytes | Pending | 02-Mar-2023 | ||
| US-20260242739-A1 | Role of hepatocyte-derived extracellular matrix and coagulation factors for the fate restoration and maintenance of human hepatocytes | Pending | 02-Mar-2023 | C12N5/067 |
PhoenixBio Signals
PhoenixBio Acquisitions (1)
PhoenixBio’s most recent deal was a Merger/Acquisition with KMT Hepatech for . The deal was made on 01-Dec-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| KMT Hepatech | 01-Dec-2017 | Merger/Acquisition | Other Healthcare Technology Systems |
PhoenixBio ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
PhoenixBio Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| KMT Hepatech | Edmonton, Canada | 2001 |
PhoenixBio FAQs
-
When was PhoenixBio founded?
PhoenixBio was founded in 2002.
-
Where is PhoenixBio headquartered?
PhoenixBio is headquartered in Higashihiroshima, Japan.
-
What is the size of PhoenixBio?
PhoenixBio has 69 total employees.
-
What industry is PhoenixBio in?
PhoenixBio’s primary industry is Drug Discovery.
-
Is PhoenixBio a private or public company?
PhoenixBio is a Public company.
-
What is PhoenixBio’s stock symbol?
The ticker symbol for PhoenixBio is 6190.
-
What is the current stock price of PhoenixBio?
As of 16-Nov-2026 the stock price of PhoenixBio is $1.56.
-
What is the current market cap of PhoenixBio?
The current market capitalization of PhoenixBio is $6.36M.
-
What is PhoenixBio’s current revenue?
The trailing twelve month revenue for PhoenixBio is $9.2M.
-
What is PhoenixBio’s annual earnings per share (EPS)?
PhoenixBio’s EPS for 12 months was $0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process